Table 3 Significant cytokines identified in 29 subjects (15 with Metastasis and 14 without Metastasis)
|  | Analytes* | Without metastasis, pg/ml (n = 15) Median (Q1, Q3) | With metastasis, pg/ml (n = 15) Median (Q1, Q3) | Sidak adjusted p-value** | Effect size |
|---|---|---|---|---|---|
1 | GCSF | 50.8 (38.5–93.2) | 1612.4 (894.9–2990.8) | 0.00012 | ∞ |
2 | IL6 | 148.2 (16.1–366.7) | 5021.7 (3832.1–6510.8) | 0.00014 | 209 |
3 | IL8 | 314.1 (27.1–1758.8) | 8517.5 (6815.4–11095.9) | 0.00014 | 209 |
4 | MCP1 | 274.9 (158.5–700.5) | 3348.5 (2093.3–6191.7) | 0.00064 | 22.3 |
5 | IL10 | 7.4 (6.3–10.6) | 103 (18.3–209.7) | 0.00245 | 11.7 |
6 | TNFa | 4.1 (3.4–6) | 8.8 (6.6–15.4) | 0.00430 | 9.5 |
7 | GMCSF | 8.8 (6.5–12.4) | 28.6 (13.5–34.4) | 0.05044 | 4.8 |
8 | Mip1a | 28.4 (9.5–49.6) | 63.1 (29.8–267.5) | 0.08302 | 4.3 |
9 | IL1B | 5.9 (3.9–7.5) | 10.9 (6.4–18.1) | 0.28424 | 3.1 |
10 | Mip1B | 12.9 (9.8–15.6) | 21.2 (13.9–35.2) | 0.32911 | 3.0 |
11 | VEGF | 110.8 (44.3–140) | 222.3 (80.8–307.5) | 0.32911 | 2.9 |
12 | IL7 | 4.6 (1–9.1) | 17.1 (1–24.8) | 0.57380 | 2.4 |
13 | IL2 | 4 (1.5–4.9) | 7.5 (1.3–11.8) | 0.70908 | 2.2 |
14 | IL4 | 9.8 (7.1–11.7) | 18.9 (0.6–42.7) | 0.74789 | 2.1 |
15 | IL_12p40 | 12.1 (6.5–14.6) | 28.4 (2.8–38.8) | 0.75598 | 2.1 |
16 | IFNa2 | 21.9 (9.8–34.8) | 55.9 (4.6–82.7) | 0.77369 | 2.0 |
17 | IL17A | 6.7 (5.2–8.7) | 12.8 (5.4–17.5) | 0.80220 | 1.9 |
18 | TNFB | 8.4 (5.5–12.4) | 15 (1.5–24.2) | 0.87285 | 1.8 |
19 | IFNg | 9.8 (7.3–10.6) | 16.3 (0.4–25.4) | 0.93782 | 1.6 |
20 | EGF | 12.8 (7.5–16.1) | 14.9 (6.3–25.9) | 0.96572 | 1.5 |
21 | IL13 | 7.1 (4.8–10.4) | 9.8 (2.4–13.8) | 0.98874 | 1.3 |
22 | IL_12p70 | 7.8 (7.2–9.8) | 10.4 (2.1–17.4) | 0.98874 | 1.3 |
23 | IL1a | 7 (6.5–9.2) | 8.2 (2.7–13.1) | 0.99124 | 1.2 |
24 | IL15 | 10.2 (7.9–14.5) | 10.2 (3.8–14.1) | 0.99124 | 1.2 |
25 | IL5 | 4.4 (3.7–5.5) | 5.4 (0.7–6.7) | 0.99124 | 1.2 |
26 | IP10 | 41.9 (26.1–66.7) | 41 (30–113) | 0.99124 | 1.1 |